Intrapleural tPA and Dornase for Loculated Parapneumonic Effusion/Empyema
For adults with loculated parapneumonic effusion or empyema inadequately drained by chest tube, administer combination intrapleural tissue plasminogen activator (tPA) 10 mg twice daily plus dornase alfa (DNase) 5 mg twice daily for 3 days through the existing chest tube. 1
Standard Dosing Protocol
The evidence-based regimen is:
- tPA 10 mg twice daily (every 12 hours) PLUS DNase 5 mg twice daily for 3 consecutive days 1, 2
- Administer through the existing chest tube after initial drainage has slowed or ceased but residual pleural collection remains 1, 2
- Each dose dwells in the pleural space for 1-2 hours with the chest tube clamped, then the tube is reopened to suction 1
Alternative Lower-Dose Regimen
- tPA 5 mg twice daily plus DNase 5 mg twice daily for 3 days may be equally effective based on retrospective data and can be used if deemed necessary 1
- This lower tPA dose may reduce bleeding risk while maintaining efficacy 3
Administration Requirements
Before initiating therapy:
- Obtain informed consent specifically addressing bleeding risk 1, 2, 4
- Ensure small-bore chest tube (≤14F) is already in place 1
- Confirm inadequate drainage from initial chest tube placement alone 1, 2
During administration:
- Instill medications through chest tube, clamp for dwell time (typically 1-2 hours), then place on continuous suction (-10 to -20 cm H₂O) 1, 5
- Monitor for complications, particularly bleeding 6
Contraindications and High-Risk Situations
Reduce tPA dose (consider 5 mg instead of 10 mg) in patients with:
- Active therapeutic anticoagulation that cannot be temporarily stopped 1, 4
- Other conditions conferring higher bleeding risk 1, 4
Absolute contraindications include:
- Active uncontrolled bleeding
- Recent neurosurgery or stroke
- Known hypersensitivity to tPA or DNase
Critical Evidence-Based Principles
Never use single-agent therapy:
- Single-agent tPA or DNase alone do NOT improve clinical outcomes and should not be used 1, 2
- The combination works synergistically: tPA breaks down fibrin deposits while DNase degrades extracellular DNA contributing to fluid viscosity 2
Do not use streptokinase:
- Streptokinase increases post-treatment complications without improving outcomes and should not be used 1, 2, 4
Expected Outcomes
Clinical benefits of tPA/DNase combination:
- Reduces length of hospital stay compared to placebo 1, 2
- Decreases likelihood of persistent fevers 1, 2
- Increases radiographic improvement with better clearance of pleural opacification 1, 2
- Avoids need for surgical intervention in most cases 7, 3
Criteria for Surgical Referral
Refer for VATS (video-assisted thoracoscopic surgery) if:
- No clinical improvement after 2-3 days of tPA/DNase therapy with persistent moderate-to-large effusion and ongoing respiratory compromise 5
- No improvement after 5-7 days of appropriate antibiotics and drainage 4
- Patient develops complications requiring surgical intervention 6
VATS is preferred over thoracotomy when surgery is required, resulting in shorter hospital stays (2.3 days shorter), less postoperative pain, fewer complications, and slightly lower mortality 1, 4
Alternative When tPA/DNase Unavailable
Saline irrigation (250 mL three times daily) can be considered when intrapleural tPA/DNase therapy or surgery is not suitable, though evidence for benefit is limited 1, 2
Common Pitfalls to Avoid
- Do not delay chest tube placement in patients with moderate-to-large effusions or respiratory distress, as delayed drainage increases morbidity and hospital stay 4
- Do not use tPA/DNase as initial therapy—it is reserved for inadequate drainage after chest tube placement 1, 2
- Do not contaminate pleural fluid pH samples with local anesthetic or heparin, as this alters pH measurement 1
- Do not proceed to early VATS or thoracotomy as initial treatment over chest tube drainage unless there are specific indications 1, 4